Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | PDE5A | O76074 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3107618 | 0.99 | EGFR (0.49) | EGFRPDGFRBKDRPDE5APOLB | |
| SCHEMBL3118952 | 0.89 | EGFR (0.49) | EGFRPDGFRBKDRPDE5APOLB | |
| Hydrochloric Acid SCHEMBL3113418 | 0.88 | EGFR (0.48) | EGFRPDGFRBKDRPDE5APOLB | |
| SCHEMBL3116693 | 0.88 | EGFR (0.43) | EGFRPDGFRBKDRPDE5AABCG2 | |
| SCHEMBL3117661 | 0.86 | EGFR (0.51) | EGFRPDGFRBKDRPDE5A | |
| SCHEMBL3120789 | 0.82 | EGFR (0.43) | EGFRPDGFRBKDR | |
| SCHEMBL2262157 | 0.82 | PDE5A (0.59) | EGFRPDGFRBKDRPDE5AABCG2 | |
| SCHEMBL3121016 | 0.81 | EGFR (0.70) | EGFRPDGFRBKDRPDE5A | |
| Hydrochloric Acid SCHEMBL3109775 | 0.81 | EGFR (0.69) | EGFRPDGFRBKDRPDE5A | |
| SCHEMBL3111895 | 0.80 | EGFR (0.44) | EGFRPDGFRBKDRPDE5AABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | claimed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | EGFR 3147/4885PDGFRB 2783/4885KDR 3722/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2648/4885PDGFRB 2627/4885KDR 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.